Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA8 | P11142 | 3/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | STAT6 | P42226 | 2/20 | 0.44 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | GAPDH | P04406 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197504 | 0.83 | CDK1 (0.48) | HSPA8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL7164519 | 0.82 | ADORA3 (0.52) | HSPA8HIF1ADOT1LSLC28A2ADORA3 | |
| SCHEMBL1976100 | 0.82 | HSPA8 (0.46) | HSPA8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL830795 | 0.82 | MAPK1 (0.50) | HSPA8CDK1CDK2HIF1AMAPK1 | |
| SCHEMBL830796 | 0.82 | MAPK1 (0.50) | HSPA8CDK1CDK2HIF1AMAPK1 | |
| SCHEMBL7622641 | 0.80 | GAPDH (0.46) | HSPA8HIF1AMAPK1STAT6DOT1L | |
| SCHEMBL19859851 | 0.80 | EHMT1 (0.43) | HSPA8HIF1AMAPK1STAT6DOT1L | |
| SCHEMBL1101261 | 0.80 | HSPA8 (0.46) | HSPA8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL724943 | 0.79 | MAPK1 (0.50) | HSPA8CDK1CDK2HIF1AMAPK1 | |
| SCHEMBL3841527 | 0.79 | DOT1L (0.50) | HSPA8CDK1CDK2HIF1AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053028-A1 | ENGINEERED CELLS FOR THERAPY | EDITAS MEDICINE, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2021138512-A1 | COMBINATION THERAPY COMPRISING A2A/A2B AND PD-1/PD-L1 INHIBITORS | INCYTE CORPORATION (US) | 2021-07-08 | — | — | WO | disclosed |
| US-20210205311-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | INCYTE CORPORATION | 2021-07-08 | — | — | US | disclosed |
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA KIRIN CO LTD (JP) | 2020-08-06 | — | — | US | disclosed |
| US-10407440-B2 | Therapeutic agent for motor disorders | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-09-10 | — | — | US | disclosed |
| EP-3378860-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-09-26 | — | — | EP | disclosed |
| EP-2433938-B1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-20170275296-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA KIRIN CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| US-9714257-B2 | Therapeutic agent for motor disorders | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-07-25 | — | — | US | disclosed |
| EP-2474544-B1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-07-12 | — | — | EP | disclosed |
| EP-0457773-A4 | N?6 -SUBSTITUTED 9-METHYLADENINES: A NEW CLASS OF ADENOSINE RECEPTOR ANTAGONISTS | — | 1993-03-10 | — | — | EP | disclosed |
| US-5189027-A | Hypotensive agent, vasoconstriction | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1993-02-23 | — | — | US | disclosed |
| EP-0488336-A1 | 2-Substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases | Yamasa Shoyu Kabushiki Kaisha (JP) | 1992-06-03 | — | — | EP | disclosed |
| US-5117830-A | Dilating the vascular system with adenosine; labeling; supplying a adenosine recetor antagonist | WHITBY RESEARCH, INC. (US) | 1992-06-02 | — | — | US | disclosed |
| EP-0457773-A1 | N?6 -SUBSTITUTED 9-METHYLADENINES: A NEW CLASS OF ADENOSINE RECEPTOR ANTAGONISTS | WHITBY RESEARCH, Inc. (US) | 1991-11-27 | — | — | EP | disclosed |
| US-5066655-A | Inhibiting adenylate cyclase | WHITBY RESEARCH, INC. (US) | 1991-11-19 | — | — | US | disclosed |
| EP-0383759-A1 | N6 SUBSTITUTED 9-METHYLADENINES: A NEW CLASS OF ADENOSINE RECEPTOR ANTAGONISTS | Whitby Research Incorporated (US) | 1990-08-29 | — | — | EP | disclosed |
| WO-1990009178-A1 | N6-SUBSTITUTED 9-METHYLADENINES: A NEW CLASS OF ADENOSINE RECEPTOR ANTAGONISTS | WHITBY RESEARCH, INC. (US) | 1990-08-23 | — | — | WO | disclosed |
| WO-1988008303-A1 | N6-SUBSTITUTED 9-METHYLADENINES: A NEW CLASS OF ADENOSINE RECEPTOR ANTAGONISTS | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1988-11-03 | — | — | WO | disclosed |
| US-4705758-A | Adenosine receptor assay and kit | WARNER-LAMBERT COMPANY (US) | 1987-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407440-B2 | Therapeutic agent for motor disorders | DDT, COMT, SLC6A3 | HSPA8 2736/4885CDK1 798/4885CCNB1 991/4885 |
| US-20170275296-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | DDT, COMT, SLC6A3 | HSPA8 2736/4885CDK1 798/4885CCNB1 991/4885 |
| US-20230053028-A1 | ENGINEERED CELLS FOR THERAPY | ACVR1, ACVRL1, ACVR2A | HSPA8 1742/4885CDK1 4224/4885CCNB1 4101/4885 |
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | HSPA8 1518/4885CDK1 1223/4885CCNB1 1601/4885 |
| US-20210205311-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | ADORA2A, ADORA2B, ADORA1 | HSPA8 2680/4885CDK1 391/4885CCNB1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.